α-melanocyte-stimulating hormone is a novel regulator of bone

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 6 47-6, 2003, Pages

  Cornish, Jillian ^a   Callon, Karen E ^a   Mountjoy, Kathleen G ^a   Bava, Usha ^a   Lin, Jian Ming ^a   Myers, Damian E ^b   Naot, Dorit ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chondrocyte; Osteoblast; Osteoclast; Systemic administration

Indexed keywords

ALPHA INTERMEDIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; BONE MARROW CULTURE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CARTILAGE CELL; CELL CULTURE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; HORMONAL REGULATION; HORMONE ACTION; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TIBIA; TRABECULAR BONE;

EID: 0038516868     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00412.2002     Document Type: Article

References (73)

1. Alderman BW, Weiss NS, Daling JR, Ure CL, and Ballard JH. Reproductive history and postmenopausal risk of hip and forearm fracture. Am J Epidemiol 124: 262-267, 1986.
2. Aspenberg P, Hansson LI, and Thorngren K-G. Modification of bone formation rate by growth hormone, melanocyte-stimulating hormone, and cortisone in the normal rat. Acta Anat (Basel) 121: 84-88, 1985.
3. Boston BA. Peripheral effects of melanocortins. In: The Melanocortin Receptors, edited by Cone RD. Totowa, NJ: Humana, 2000, p. 143-169.
4. Boston BA and Cone RD. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology 137: 2043-2050, 1996.
5. Buchanan CM, Phillips ARJ, and Cooper GJS. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 360: 431-439, 2001.
6. Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, and Cone RD. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 4: 605-611, 2001.
7. Cornish J, Callon KE, Bava U, Coy DH, Mulvey TB, Murray MAF, Cooper GJS, and Reid IR. Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice. J Endocrinol 170: 251-257, 2001.
8. Cornish J, Callon K, Bava U, Grey A, Xu X, Buchanan CM, Cooper GJS, and Reid IR. The novel hormone, preptin, is another bone-active product of the pancreatic beta cell (Abstract). J Bone Miner Res 17, Suppl 1: S428, 2002.
9. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Meyers DE, Nicholson GC, and Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175: 405-415, 2002.
10. Cornish J, Callon KE, Cooper GJS, and Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 207: 133-139, 1995.
11. Cornish J, Callon KE, Gasser JA, Bava U, Gardiner EM, Coy DH, Cooper GJS, and Reid IR. Systemic administration of a novel octapeptide, amylin-(1-8), increases bone volume in male mice. Am J Physiol Endocrinol Metab 279: E730-E735, 2000.
12. Cornish J, Callon KE, King AR, Cooper GJS, and Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol Endocrinol Metab 38: E694-E699, 1998.
13. Cornish J, Callon KE, Lin CQX, Xiao CL, Mulvey TB, Cooper GJS, and Reid IR. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol Endocrinol Metab 277: E779-E783, 1999.
14. Cornish J, Callon KE, and Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 59: 492-495, 1996.
15. De Rotte AA, Bouman HJ, and van Wimersma Greidanus TB. Relationships between alpha-MSH levels in blood and in cerebrospinal fluid. Brain Res Bull 5: 375-381, 1980.
16. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen JH, Vinson C, Rueger JM, and Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000.
17. Dumont LM, Wu C-S, Aschkenasi CJ, Elmquist JK, Lowell BB, and Mountjoy KG. Mouse melanocortin-4 receptor gene 5′-flanking region imparts cell specific expression in vitro. Mol Cell Endocrinol 184: 173-185, 2001.
18. Elmquist JK, Elias CF, and Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22: 221-232, 1999.
19. Ensrud KE, Lipschutz RC, Cauley JA, Seeley D, Nevitt MC, Scott J, Orwoll ES, Genant HK, and Cummings SR. Body size and hip fracture risk in older women - a prospective study. Am J Med 103: 274-280, 1997.
20. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, and Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141: 3072-3079, 2000.
21. Farmer ME, Harris T, Madans JH, Wallace RB, CoroniHuntley J, and White LR. Anthropometric indicators and hip fracture. The NHANES I epidemiologic follow-up study. J Am Geriatr Soc 37: 9-16, 1989.
22. Farooqi IS, Yeo GSH, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, and O'Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 deficiency. J Clin Invest 106: 271-279, 2000.
23. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, and Born J. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 86: 1144-1148, 2001.
24. Felson DT, Zhang YQ, Hannan MT, and Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women. The Framingham Study. J Bone Miner Res 8: 567-573, 1993.
25. Gafny M, Silbergeld A, Klinger B, Wasserman M, and Laron Z. Comparative effects of GH, IGF-1 and insulin on serum sex hormone binding globulin. Clin Endocrinol 41: 169-175, 1994.
26. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, and Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 268: 8246-8250, 1993.
27. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, and Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 268: 15174-15179, 1993.
28. Gu W, Tu Z, Kleyn PW, Kissebah A, Duprat L, Lee J, Chin W, Maruti S, Deng N, Fisher SL, Franco LS, Burn P, Yagaloff KA, Nathan J, Heymsfield S, Albu J, Pi-Sunyer FX, and Allison DB. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 48: 635-639, 1999.
29. Gureyev TE, Stevenson AW, Paganin D, Mayo SC, Pogany A, Gao D, and Wilkins SW. Quantitative methods in phasecontrast x-ray imaging. J Digit Imaging 13: 121-126, 2000.
30. Hickman J and McElduff A. Insulin promotes growth of the cultured rat osteosarcoma cell line UMR-106-01: an osteoblast-like cell. Endocrinology 124: 701-706, 1989.
31. Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, Gerber G, Sina M, Gorg T, Mayer H, Siegfried W, Fichter M, Remschmidt H, and Hebebrand J. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 84: 1483-1486, 1999.
32. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RG, Smith FJ, Campfield LA, Burn P, and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141, 1997.
33. Hutchinson TA, Polansky SM, and Feinstein AR. Postmenopausal oestrogens protect against fractures of hip and distal radius. Lancet ii: 705-709, 1979.
34. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Tanaka T, Furuta M, Araki-Sasaki R, Hori Y, Naktani K, Yano Y, and Adachi Y. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab 86:1921-1924, 2001.
35. Khosla S, Atkinson EJ, Riggs BL, and Melton LJ. Relationship between body composition and bone mass in women. J Bone Miner Res 11: 857-863, 1996.
36. Kiel DP, Felson DT, Anderson JJ, Wilson PW, and Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 317: 1169-1174, 1987.
37. Krude H, Biebermann H, Luck W, Horn R, Brabant G, and Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157, 1998.
38. Lau EMC, Chan YH, Chan M, Woo J, Griffith J, Chan HHL, and Leung PC. Vertebral deformity in Chinese men: prevalence, risk factors, bone mineral density, and body composition measurements. Calcif Tissue Int 66: 47-52, 2000.
39. Loukovaara M, Carson M, and Adlercreutz H. Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. J Clin Endocrinol Metab 80: 160-164, 1995.
40. Lowe C, Cornish J, Martin TJ, and Reid IR. Effects of leukemia inhibitory factor on bone resorption and DNA synthesis in neonatal mouse calvaria. Calcif Tissue Int 49: 394-397, 1991.
41. Marcus R, Greendale G, Blunt BA, Bush TL, Sherman S, Sherwin R, Wahner H, and Wells B. Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res 9: 1467-1476, 1994.
42. Mazess R, Barden H, Ettinger B, Johnston C, DawsonHughes B, Baran D, Powell M, and Notelovitz M. Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner 2: 211-219, 1987.
43. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, and Cone RD. Localization of the melanocortin-4 receptor in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8: 1298-1308, 1994.
44. Mountjoy KG, Robbins LS, Mortrud MT, and Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248-1251, 1992.
45. Muscaritoli M, Gleason JR, Meguid MM, and Lukaski HC. Densitometry-based equations for estimating body composition in Fischer rats. Nutrition 9: 439-445, 1993.
46. Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, and Marcus C. Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J Clin Endocrinol Metab 86: 4849-4853, 2001.
47. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, and Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 95: 28-31, 1981.
48. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, and Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and osteoporosis. J Clin Invest 72: 1396-1409, 1983.
49. Peiris AN, Stagner JI, Plymate SR, Vogel RL, Heck M, and Samols E. Relationship of insulin secretory pulses to sex hormone-binding globulin in normal men. J Clin Endocrinol Metab 76: 279-282, 1993.
50. Pluijm SMF, Visser M, Smit JH, Popp-Snijders C, Roos JC, and Lips P. Determinants of bone mineral density in older men and women: body composition as mediator. J Bone Miner Res 16: 2142-2151, 2001.
51. Pun KK, Lau P, and Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res 4: 853-62, 1989.
52. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, and Christiansen C. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. J Bone Miner Res 14: 1622-1627, 1999.
53. Reid IR. Relationships among body mass, its components, and bone. Bone 31: 547-555, 2002.
54. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TMT, and Cundy TF. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab 75: 45-51, 1992.
55. Reid IR, Evans MC, and Ames RW. Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. Osteoporos Int 4: 362-367, 1994.
56. Reid IR, Evans MC, Cooper GJS, Ames RW, and Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol Endocrinol Metab 265: E655-E659, 1993.
57. Reid IR, Lowe C, Cornish J, Skinner SJM, Hilton DJ, Willson TA, Gearing DP, and Martin TJ. Leukemia inhibitory factor: a novel bone-active cytokine. Endocrinology 126: 1416-1420, 1990.
58. Reid IR, Plank LD, and Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 75: 779-782, 1992.
59. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, RoselliRehfuss L, Baack E, Mountjoy KG, and Cone RD. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72: 827-834, 1993.
60. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro LB, Entwistle ML, Simerly RB, and Cone RD. Identification of a receptor for gamma melanocortin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90: 8856-8860, 1993.
61. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, and Meunier PJ. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS prospective study. Osteoporos Int 8: 247-254, 1998.
62. Seeley RJ, Yagaloff KA, Fisher SL, Bura P, Thiele TD, van Dijk G, Baskin DG, and Schwartz MW. Melanocortin receptors in leptin effects. Nature 390: 349, 1997.
63. Shimizu H, Tanaka Y, Sato N, and Mori M. Alpha-melanocyte-stimulating hormone (MSH) inhibits insulin secretion in HIT-T 15 cells. Peptides 16: 605-608, 1995.
64. Stenstrom A, Hansson LI, and Thorngren K-G. Influence of alpha-MSH and ACTH on cortical bone remodelling in hypophysectomized rats. Experientia 35: 132-133, 1979.
65. Stolk RP, Vandaele PLA, Pols HAP, Burger H, Hofman A, Birkenhager JC, Lamberts SWJ, and Grobbee DE. Hyperinsulinemia and bone mineral density in an elderly populationthe Rotterdam Study. Bone 18: 545-549, 1996.
66. Taaffe DR, Cauley JA, Danielson M, Nevitt MC, Lang TF, Bauer DC, and Harris TB. Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study. J Bone Miner Res 16: 1343-1352, 2001.
67. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, and Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317, 2002.
68. Usategui R, Oliver C, Vaudry H, Lombardi G, Rozenberg I, and Mourre AM. Immunoreactive alpha-MSH and ACTH levels in rat plasma and pituitary. Endocrinology 98: 189-196, 1976.
69. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, and Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obestiy. J Clin Invest 106: 253-262, 2000.
70. Walker WV, Russell JE, Simmons DJ, Scheving LE, Cornelissen G, and Halberg F. Effect of an adrenocorticotropin analogue, ACTH 1-17, on DNA synthesis in murine metaphyseal bone. Biochem Pharmacol 34: 1191-1196, 1985.
71. Wilkins SW, Gureyev TE, Gao D, Pogany A, and Stevenson AW. Phase-contrast imaging using polychromatic hard x-rays. Nature 384: 335-338, 1996.
72. Williams AR, Weiss NS, Ure CL, Ballard J, and Daling JR. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol 60: 695-699, 1982.
73. Yaswen L, Diehl N, Brennan MB, and Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070, 1999.